Adjuvant Therapy: Melanoma

Table 1

Phase II trials of IFN-α for metastatic melanoma.

Study reference	No. of enrolled patients (followup)	Therapy and IFN subspecies	Dose—treatment arm (MU/m^2)	Schedule—treatment arm	ORR	CR	PR
Ernstoff et al. 1983 [82]	17	α2b	10–100	5 d/week × 1 month	N/A	N/A	2
Creagan et al. 1984 [83]	23	α2a	50	Thrice weekly × 12 weeks	20	1	5
Creagan et al. 1985 [84]	350	α2a + cimetidine	50	Thrice weekly × 12 weeks	23	0	8
Creagan et al. 1984 [85]	31	α2a	12	Thrice weekly × 12 weeks	23	3	4
Legha et al. 1987 [86]	62	α2a	1st arm—escalating (3–36 × 10^6 U/d); 2nd arm—fixed dose (18 × 10^6 U/d)	1st arm—daily during induction followed by thrice weekly; 2nd arm—thrice weekly	1st—12.9%; 2nd—16.1%	1st 0; 2nd 0	1st—9.7%; 2nd—6.5%
Hersey et al. 1985 [87]	200	α2a	15–50	Thrice weekly	10	2	0
Neefe et al. 1990 [88]	97	α2a	Escalating: 3 to 36 × 10^6 U	Daily for 10 days then 70 days total	8	6	2
Dorval et al. 1986 [89]	22	α2b	10	Thrice weekly	24	2	4
Coates et al. 1986 [90]	15	α2a	20	5 d/week every 2 weeks	0	0	0